156 related articles for article (PubMed ID: 18821431)
1. Epidemiology, pathology and treatment of non-follicular indolent lymphomas.
Landgren O; Tilly H
Leuk Lymphoma; 2008; 49 Suppl 1():35-42. PubMed ID: 18821431
[TBL] [Abstract][Full Text] [Related]
2. Transformation of marginal zone lymphoma (and association with other lymphomas).
Casulo C; Friedberg J
Best Pract Res Clin Haematol; 2017; 30(1-2):131-138. PubMed ID: 28288708
[TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical patterns of follicular dendritic cell meshwork and Ki-67 in small B-cell lymphomas].
Shi YF; Li XH
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):222-6. PubMed ID: 23928527
[TBL] [Abstract][Full Text] [Related]
4. Indolent B-cell non-Hodgkin's lymphomas.
Seng JE; Peterson BA
Oncology (Williston Park); 1997 Dec; 11(12):1883-94, 1987; discussion 1901-2, 1. PubMed ID: 9436191
[TBL] [Abstract][Full Text] [Related]
5. Pathology of indolent B-cell neoplasms other than follicular lymphoma.
Sakata S; Tsuyama N; Takeuchi K
J Clin Exp Hematop; 2014; 54(1):11-22. PubMed ID: 24942942
[TBL] [Abstract][Full Text] [Related]
6. Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.
Quintanilla-Martinez L; Sander B; Chan JK; Xerri L; Ott G; Campo E; Swerdlow SH
Virchows Arch; 2016 Feb; 468(2):141-57. PubMed ID: 26416032
[TBL] [Abstract][Full Text] [Related]
7. Marginal zone-related neoplasms of splenic and nodal origin.
Arcaini L; Paulli M; Boveri E; Magrini U; Lazzarino M
Haematologica; 2003 Jan; 88(1):80-93. PubMed ID: 12551831
[TBL] [Abstract][Full Text] [Related]
8. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
9. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
Williams ME; Hong F; Gascoyne RD; Wagner LI; Krauss JC; Habermann TM; Swinnen LJ; Schuster SJ; Peterson CG; Sborov MD; Martin SE; Weiss M; Ehmann WC; Horning SJ; Kahl BS
Br J Haematol; 2016 Jun; 173(6):867-75. PubMed ID: 26970533
[TBL] [Abstract][Full Text] [Related]
10. Indolent lymphomas of mature B lymphocytes.
Kurtin PJ
Hematol Oncol Clin North Am; 2009 Aug; 23(4):769-90. PubMed ID: 19577169
[TBL] [Abstract][Full Text] [Related]
11. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection.
Levine AM; Sadeghi S; Espina B; Tulpule A; Nathwani B
Cancer; 2002 Mar; 94(5):1500-6. PubMed ID: 11920507
[TBL] [Abstract][Full Text] [Related]
13. Nodal and splenic marginal zone B cell lymphomas.
Mollejo M; Camacho FI; Algara P; Ruiz-Ballesteros E; García JF; Piris MA
Hematol Oncol; 2005; 23(3-4):108-18. PubMed ID: 16307458
[TBL] [Abstract][Full Text] [Related]
14. Prognostic assessment in patients with indolent B-cell lymphomas.
Arcaini L; Rattotti S; Gotti M; Luminari S
ScientificWorldJournal; 2012; 2012():107892. PubMed ID: 22919288
[TBL] [Abstract][Full Text] [Related]
15. Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies.
van den Brand M; Scheijen B; Hess CJ; van Krieken JHJ; Groenen PJTA
Blood Rev; 2017 Nov; 31(6):426-435. PubMed ID: 28802906
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma.
Ikeda JI; Kohara M; Tsuruta Y; Nojima S; Tahara S; Ohshima K; Kurashige M; Wada N; Morii E
Hum Pathol; 2017 Jan; 59():70-79. PubMed ID: 27666766
[TBL] [Abstract][Full Text] [Related]
17. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Akyurek N; Ren Y; Rassidakis GZ; Schlette EJ; Medeiros LJ
Cancer; 2006 Oct; 107(8):1844-51. PubMed ID: 16983704
[TBL] [Abstract][Full Text] [Related]
18. Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies.
Smyth E; Cheah CY; Seymour JF
Cancer Treat Rev; 2023 Feb; 113():102510. PubMed ID: 36634434
[TBL] [Abstract][Full Text] [Related]
19. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.
Al-Hamadani M; Habermann TM; Cerhan JR; Macon WR; Maurer MJ; Go RS
Am J Hematol; 2015 Sep; 90(9):790-5. PubMed ID: 26096944
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
